ArticleIJID regions2025
Outcomes and microbiological patterns of bacteremia in chemotherapy-related febrile neutropenia at a tertiary facility in Kenya.
Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Febrile neutropenia (FN) is a major cause of mortality and morbidity in patients with malignancy post-chmotherapy. Current guidelines for managing FN recommend starting empiric antibiotic therapy (EAT) promptly. The choice of antibiotic is based on the patient's condition, local data on common microorganisms isolated, and their resistance patterns. Of note, there is a growing trend of isolating multi-drug-resistant gram-negative bacteria in these patients. In sub-Saharan Africa, there are insufficient data on the mortality rates of FN. There is also a lack of local epidemiologic data on the frequently isolated microorganisms and their antibiotic resistance patterns. This makes it challenging to determine the appropriate EAT for patients with FN. This study aimed to determine the mortality rates of FN in patients with cancer and characterize the isolated microorganisms and their resistance patterns. Methods: This was a retrospective descriptive study of adult patients with cancer hospitalized with FN post-chemotherapy between January 2017 and July 2022 at Aga Khan University Hospital, Kenya. Continuous variables are expressed as medians with inter-quartile ranges whereas categorical variables are expressed as frequencies and percentages. Results: A total of 90 episodes of FN involving 50 unique patients were identified from medical records. The median age was 42.8 years (inter-quartile range: 31.3-65.0). Male patients accounted for 67.0% (n = 60). Hematologic malignancies accounted for 90.0% (n = 81). The mortality rate was 26.0% (n = 13), with 84.6% (n = 11) having a hematologic malignancy. Of the 90 episodes, 27.8% (25) had positive blood cultures; 68.0% (17) were gram-negative, 24.0% (six) were gram-positive, and 8.0% (two) were candida species. Conclusions: The study found a higher mortality rate in patients with FN in East Africa than in North America. Gram-negative bacteria were the most commonly isolated pathogens in blood cultures, with a growing concern over the increasing prevalence of multi-drug-resistant strains. Further multi-centered studies involving larger sample sizes are required to help develop regional guidelines for the choice of EAT in the management of FN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.